Fenbendazole and Ivermectin for Cancer: 2026 Mutation Research

Author and Medical Reviewer: Dr. Imran Khan, MD, IFMCP

Last Updated: September 23, 2026

Why Cancer Researchers Are Looking at Fenbendazole and Ivermectin

Fenbendazole and ivermectin are antiparasitic drugs that continue to receive scientific attention for their potential anticancer activity. Preclinical research has examined effects involving microtubule disruption, cellular metabolism, p53-related activity, and signaling pathways involved in cancer-cell growth and survival.

Together, these findings provide a biological rationale for continued investigation in cancer research. Most of the evidence remains laboratory- or animal-based, with limited clinical evidence available to determine anticancer efficacy or mutation-specific benefit in humans.

Medical Disclaimer: This article is for educational purposes only and is not medical advice or a treatment protocol. Fenbendazole and ivermectin should not replace established cancer treatments. Any use during cancer care should be discussed with your treating oncology team.

What the Evidence Shows So Far

Research on fenbendazole and ivermectin spans laboratory studies, animal models, and emerging human research, with different levels of evidence across each area.

• Laboratory Research: Multiple potential anticancer mechanisms identified
• Animal Research: Preclinical findings reported in some models
• Human Evidence: Limited and still developing
• Mutation-Specific Treatment: Not clinically established
• Clinical Research: Emerging clinical investigation

How Cancer Mutations Can Influence Treatment

Cancer develops through genetic and cellular changes that affect how cells grow, divide, repair damage, and respond to signals. Certain genetic alterations and biomarkers can help oncologists select established targeted therapies or immunotherapies for specific cancers.

Genetic alterations involving TP53, BRCA1/2, KRAS, BRAF, and CDK4, along with immune biomarkers involving PD-1 and PD-L1, may be considered in cancer research and treatment. Research into related biological pathways can help scientists understand potential mechanisms, although pathway activity is distinct from directly targeting a specific mutation or biomarker.

How Fenbendazole and Ivermectin Are Being Studied in Cancer

Preclinical research has identified several potential anticancer mechanisms:

• Fenbendazole and microtubules: Laboratory research found that fenbendazole moderately disrupted microtubule activity involved in cell division in cancer-cell models.
• Fenbendazole and cellular metabolism: In the same preclinical study, fenbendazole reduced glucose uptake and affected pathways associated with cancer-cell death.
• Ivermectin and signaling pathways: Preclinical research has examined effects involving Wnt/β-catenin, Akt/mTOR, and other signaling pathways associated with cancer-cell growth and survival.
• Ivermectin and cancer-cell survival: Experimental studies have reported effects involving proliferation and apoptosis across several laboratory cancer models.

These findings show that fenbendazole and ivermectin can affect several cellular processes and signaling pathways relevant to cancer biology. Most of this evidence remains preclinical, so the clinical significance of these effects in patients is still being investigated.

Research Note: The mutation and pathway findings discussed below are primarily preclinical. They provide insight into potential biological mechanisms but should not be viewed as evidence of a clinically validated mutation-targeted therapy.

How Do Fenbendazole and Ivermectin Relate to Cancer Mutations and Pathways?

Research has examined how fenbendazole and ivermectin may influence pathways involved in cancer growth, survival, metabolism, and immune activity.

• TP53/p53: Fenbendazole showed p53-related activity in laboratory models, with wild-type p53 cells appearing more sensitive than p53-mutant or p53-null cells.
• Wnt/β-catenin and Akt/mTOR: Ivermectin has been observed to influence these signaling pathways involved in cancer-cell growth and survival.
• PD-1 and PD-L1: These are immune checkpoint proteins rather than cancer mutations and are relevant to ongoing research involving cancer immunotherapy.
• BRCA1/2: These genes are involved in DNA repair, but direct evidence involving fenbendazole or ivermectin remains limited.
• KRAS and BRAF: These mutations affect cell-growth signaling pathways, but a mutation-specific role for either drug remains unclear.
• CDK4: CDK4 helps regulate the cell cycle, an area also examined in experimental research.

These findings highlight areas of scientific interest involving cancer pathways, genetic changes, and immune activity that continue to be studied.

What Human Evidence Is Available?

Human research remains limited but is developing. A 2024 review published in Anticancer Research reviewed fenbendazole’s pharmacokinetics, experimental anticancer activity, and safety data, while identifying the need for human trials to determine appropriate dosing and tolerability.

For ivermectin, a 2025 review found substantial preclinical research but noted that large-scale randomized controlled trials have not confirmed anticancer benefits. In 2026, the Phase 2 ICONIC study was registered to evaluate ivermectin with immune checkpoint inhibitor therapy in adults with solid tumors, focusing on safety and immune-related effects. The study has not reported efficacy results.

Further clinical trials are needed to clarify dosing, safety, and whether these experimental findings translate to meaningful benefits in patients.

What Are the Safety and Treatment Considerations?

Fenbendazole and ivermectin have important limitations when considered during cancer care. Before considering either drug, patients should understand the following safety and treatment concerns:

• Fenbendazole is an FDA-approved animal drug ingredient and is not approved for human use. Ivermectin is FDA-approved for certain human parasitic infections, but not for cancer.
• Cancer-specific dosing and treatment combinations remain areas requiring clinical research.
• Potential interactions with cancer treatments and other medications require medical consideration.
• Self-administered fenbendazole has been associated with severe liver injury in a 2026 case report, raising an additional safety consideration for patients.
• Neither drug should replace established cancer treatments when medically indicated.

Patients should discuss either drug with their treating oncology team rather than rely on veterinary products or online protocols.

How Cancer Testing Can Support Personalized Care

Cancer testing can provide information about tumor characteristics and biomarkers that may help inform personalized care. RGCC Testing and Circulating Tumor Cell Testing may provide additional clinical context.

For patients considering repurposed drugs, IHAWMD's Repurposed Drug Assay may provide additional information for physician review. Testing, however, cannot determine whether fenbendazole, ivermectin, or another investigational drug will be effective for an individual patient.

Discuss Emerging Cancer Research With IHAWMD

If you are evaluating repurposed drugs, cancer testing, or other complementary approaches, IHAWMD offers Personalized Cancer Care to help place these options within the context of your existing oncology care.

Our medical team can help you understand the available evidence, testing options, and emerging research. Schedule a consultation to discuss your questions and next steps.

About Dr. Imran Khan

Dr. Imran Khan, MD, IFMCP, has over 15 years of experience in internal medicine and is certified by the Institute for Functional Medicine. He completed his internal medicine residency at Case Western Reserve University and MetroHealth Medical Center, with professional experience at Cleveland Clinic, Baylor St. Luke’s Medical Center, and Memorial Hermann Memorial City.

At Internal Healing and Wellness MD, Dr. Khan provides personalized and functional medicine approaches that complement patients’ established medical care.

References

• Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. doi:10.1038/s41598-018-30158-6.
• Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research. 2018;8(2):317–331. PMID: 29511601.
• Nguyen J, Nguyen TQ, Han BO, Hoang BX. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research. 2024;44(9):3725–3735. doi:10.21873/anticanres.17197.
• Patel Y, Chawla J, Parmar MS. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? Current Oncology Reports. 2025;27(9):1070–1079. doi:10.1007/s11912-025-01704-z.
• Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P, Slaninová I. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. 2019;24(11):2152. doi:10.3390/molecules24112152.
• ClinicalTrials.gov. Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC). Phase 2. NCT07487805.
• Krishnan A, Lucas K, Maas L, Woreta TA. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis – the importance of structured causality assessment: A case report. World Journal of Clinical Cases. 2026;14(2):116700. doi:10.12998/wjcc.v14.i2.116700.